Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
Hear from Experts on the Management of SEA and co-morbid CRSwNP patients
The image above is a fictional patient for illustrative purposes.
Nucala (mepolizumab) Indication
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. Nucala is also indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.1
Nucala is not reimbursed for CRSwNP in the UK.
Expert Profiles
Professor Claire Hopkins
Claire Hopkins is a Consultant Rhinologist at Guy’s Hospital, a large tertiary referral centre in London, UK, with a clinical practice covering the breadth of rhinology including sinusitis, anterior skull base work and facial plastics. She is a Professor of Rhinology at King’s College London. She is the Secretary General of the European Rhinological Society, Past-President of the Royal Society of Medicine’s Section of Laryngology and Rhinology and of the British Rhinological Society. She is co-author of the European Position Statement on Rhinosinusitis and Nasal Polyps and the International Consensus on Rhinosinusitis. She has a large research program covering all aspects of medical and surgical management of rhinitis and sinus disease, with a focus on improving outcomes in the management of nasal polyps. She has recently been involved in highlighting the link between COVID-19 and loss of smell and taste.
Dr Pujan Patel
Dr Pujan Patel is a Consultant in Respiratory Medicine with expertise in Severe Asthma management at the Royal Brompton Hospital. He is also Honorary Senior Clinical Lecturer at Imperial College, NHLI and Adjunct Associate Professor at St. Louis University Hospital, USA. Having completed fellowships in both Respiratory and Critical Care Medicine in the United States, he joined the Brompton’s Severe Asthma service in managing the UK’s largest stand-alone cohort of severe asthmatics on asthma biologic therapies. As a full time clinician, he is responsible for the assessment of new tertiary referrals and conducts weekly biologic MDTs to identify suitable biologic candidates. He serves on various subgroup committees for the British Thoracic Society (BTS) and American Thoracic Society (ATS) and continues to engage in medical education and teaching both domestically and internationally.
Abbreviations
CRSwNP, chronic rhinosinusitis with nasal polyps; SEA, severe eosinophilic asthma
References
- Nucala Summary of Product characteristics
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.
October 2025 I PM-GB-MPL-WCNT-250007 (V1.0)
